Generation of circulating tumor cell derived organoids through enrichment by leukapheresis - A novel drug screening system in metastatic prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON29626

Enrollment

Registered

2016-12-07

Start date

2016-12-07

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer CRPC HSPC Metastatic prostate cancer

Interventions

leukapheresis

Eligibility

Inclusion criteria

Inclusion criteria: - Metastatic prostate cancer. - Intention to start (new) line of systemic treatment. - Written informed consent of the patient. - Age ≥ 18 years. - WHO performance status ≤2. - ≥ 2 adequate peripheral veins as access point for leukapheresis.

Exclusion criteria

Exclusion criteria: - Low CTC count. - Patients with a known hypersensitivity to the used LA-anticoagulant (ACD). - Current ADT - Hemorrhage disease and/or coagulation disorder. - Inadequate liver function. - Inadequate renal function. - Inadequate hematology and coagulation status. - Use of anticoagulation at time of leukapheresis, unless medication can either be safely stopped or counteracted.

Design outcomes

Primary

Measure	Time frame
The rate of successfully cultured organoids from CTCs obtained by LA.	—

Secondary

Measure	Time frame
The collection efficiency of CTCs by LA.	—

Contacts

Public ContactA.C. de Jong

afdeling Interne Oncologie - Erasmus MC Kanker Instituut, kamer Be-414a

a.c.dejong@erasmusmc.nlTel.: 010-7044375

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)